Jean-Paul Kress

Directeur Général chez VOR BIOPHARMA INC.

Profil

Jean-Paul Kress currently works at Vor Biopharma, Inc., as Chairman, President & Chief Executive Officer from 2025, Syntimmune, Inc., as President & Director, and Sanofi, as Independent Director from 2025.
Dr. Kress also formerly worked at Sanofi Pasteur MSD SNC, as President & Chief Executive Officer from 2011 to 2015, MorphoSys AG, as CEO & Chairman-Management Board from 2019 to 2024, ERYTech Pharma SA, as Chairman from 2019 to 2023, Sarepta Therapeutics, Inc., as Independent Director from 2015 to 2017, Quantum Genomics SA, as Director from 2018 to 2019, Biogen, Inc., as President-International & Executive Vice President from 2017 to 2018, Genzyme Corp., as Senior Vice President & Head-North America from 2015 to 2017, Gilead Sciences SAS, as Vice President-US Sales & Marketing, and Abbott France SAS, as General Manager-Denmark.
Dr. Kress received his undergraduate degree in 1991 and graduate degree in 1992 from École Normale Supérieure and doctorate degree in 1991 from Faculté De Médecine Necker Enfants Malades Université.

Postes actifs de Jean-Paul Kress

Sociétés	Poste	Début
SANOFI	Directeur/Membre du Conseil	01/01/2025
VOR BIOPHARMA INC.	Directeur Général	25/06/2025
Syntimmune, Inc.	President	03/01/2018

Anciens postes connus de Jean-Paul Kress

Sociétés	Poste	Fin
MORPHOSYS AG	Directeur Général	06/06/2024
ERYTech Pharma SA	Président	23/06/2023
QUANTUM GENOMICS	Directeur/Membre du Conseil	24/06/2019
BIOGEN INC.	Corporate Officer/Principal	01/01/2018
SAREPTA THERAPEUTICS, INC.	Directeur/Membre du Conseil	06/06/2017